Home » Stocks » MDWD

MediWound Ltd. (MDWD)

Stock Price: $3.80 USD -0.28 (-6.86%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 103.53M
Revenue (ttm) 23.17M
Net Income (ttm) -9.59M
Shares Out 27.25M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $3.80
Previous Close $4.08
Change ($) -0.28
Change (%) -6.86%
Day's Open 4.07
Day's Range 3.80 - 4.11
Day's Volume 149,348
52-Week Range 2.90 - 6.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MediWound Ltd (NASDAQ: MDWD) has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC).  In parallel, an investigator-initiated Phase 2 trial of MW005 in non-melanoma skin ca...

4 days ago - Benzinga

MediWound Ltd (NASDAQ: MDWD) has announced topline results from Phase 3 pediatric study with NexoBrid to treat severe thermal burns.  The 145-subject study met its three primary endpoints.

1 week ago - Benzinga

NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD).

1 week ago - PRNewsWire

Study Findings D emonstrate S trong R esults in Debriding V enous L eg U lcers and D iabetic F oot U lcers

3 weeks ago - GlobeNewsWire

Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid Bi...

Other stocks mentioned: VCEL
1 month ago - Benzinga

Vericel Corporation's (NASDAQ:VCEL) development partner, MediWound Ltd (NASDAQ:MDWD), received a complete response letter from FDA regarding the NexoBrid application seeking approval for eschar removal ...

Other stocks mentioned: VCEL
1 month ago - Benzinga

Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy

1 month ago - GlobeNewsWire

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

Other stocks mentioned: AEZS, AMRN, DRRX, GLBS, LOTZ, NTEC
1 month ago - PennyStocks

Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021 Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021

1 month ago - GlobeNewsWire

MediWound (MDWD) delivered earnings and revenue surprises of 16.67% and 10.32%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

First Quarter Revenues of $5.8 Million, an Increase of 32% Year-over-Year

2 months ago - GlobeNewsWire

MediWound (NASDAQ:MDWD) releases its next round of earnings this Wednesday, May 05. Here is Benzinga's essential guide to MediWound's Q1 earnings report.

2 months ago - Benzinga

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

YAVNE, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and r...

3 months ago - GlobeNewsWire

Data Expected Second-Half 2021 Data Expected Second-Half 2021

3 months ago - GlobeNewsWire

Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time

4 months ago - GlobeNewsWire

YAVNE, Israel, Feb. 25, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and re...

5 months ago - GlobeNewsWire

MediWound (MDWD) delivered earnings and revenue surprises of 45.45% and 19.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Fourth Quarter Revenues of $6.7 Million - Up 23% and Full-Year 20 20 Revenues of $ 2 1.8 Million - Product Revenue Up 117%

5 months ago - GlobeNewsWire

Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021

5 months ago - GlobeNewsWire

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

YAVNE, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound...

5 months ago - GlobeNewsWire

YAVNE, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound...

5 months ago - GlobeNewsWire

Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.

Other stocks mentioned: ALNA, ALRN, MBIO, MCHX, OBSV, RWLK
5 months ago - InvestorPlace

Phase 2 Adaptive Design Study Sample Size Reduced to 120 Patients

6 months ago - GlobeNewsWire

YAVNE, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound...

6 months ago - GlobeNewsWire

MediWound recently reported an encouraging Q3 with a beat on EPS and revenue. It looks as if the company is easily weathering the pandemic with support from BARDA purchases. I have already established a...

7 months ago - Seeking Alpha

Data to be Published in a Peer-Reviewed Journal in First Half 2021 Data to be Published in a Peer-Reviewed Journal in First Half 2021

7 months ago - GlobeNewsWire

YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound...

7 months ago - GlobeNewsWire

MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and 2.16%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Shares of MediWound (NASDAQ:MDWD) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share rose 36.36% over the past year to ($0.07), which beat the estimate of ($...

8 months ago - Benzinga

Total Third Quarter R evenues of $6.6 Million Increased 29 % Y ear-over- Y ear

8 months ago - GlobeNewsWire

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

YAVNE, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound...

8 months ago - GlobeNewsWire

Top-line Data is Expected in the Second Half of 2021 Top-line Data is Expected in the Second Half of 2021

9 months ago - GlobeNewsWire

Bromelain Degradation of Biofilms Could Provide Clinically Meaningful Benefits in Wound Healing Bromelain Degradation of Biofilms Could Provide Clinically Meaningful Benefits in Wound Healing

9 months ago - GlobeNewsWire

YAVNE, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in ...

10 months ago - GlobeNewsWire

MediWound: An Underfollowed Opportunity At A Discount

10 months ago - Seeking Alpha

YAVNE, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in se...

10 months ago - GlobeNewsWire

YAVNE, Israel and CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the Biomedic...

Other stocks mentioned: VCEL
11 months ago - GlobeNewsWire

Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and -15.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Submitted Biological License Application to the FDA for NexoBrid  EscharEx U.S. Phase 2 Study Resumed Patient Screening

11 months ago - GlobeNewsWire

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

YAVNE, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wou...

1 year ago - GlobeNewsWire

MediWound (MDWD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

YAVNE, Israel, June 30, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn...

1 year ago - GlobeNewsWire

Mediwound, An Attractive Opportunity Through The Coronavirus Crisis

1 year ago - Seeking Alpha

About MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological dr... [Read more...]

Industry
Biotechnology
IPO Date
Mar 20, 2014
CEO
Sharon Malka
Employees
75
Stock Exchange
NASDAQ
Ticker Symbol
MDWD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for MediWound stock is "Strong Buy." The 12-month stock price forecast is 7.00, which is an increase of 84.21% from the latest price.

Price Target
$7.00
(84.21% upside)
Analyst Consensus: Strong Buy